Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women

Climacteric

Volumn 13, Issue 1, 2010, Pages 55-62

  Erdogan, G ^a   Aydin, M ^b   Tasdemir, N ^a   Doganay, M ^a   Batioglu, S ^a  

^a Zekai Tahir Burak Women's Health and Education Hospital   (Turkey)

^b FATIH UNIVERSITY   (Turkey)

Author keywords

Asymmetric dimethylarginine; Cardiovascular risk; Non oral estrogen

Indexed keywords

BIOLOGICAL MARKER; ESTROGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE; N(G),N(G) DIMETHYLARGININE; TRIACYLGLYCEROL;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ESTROGEN THERAPY; FEMALE; HUMAN; HYSTERECTOMY; MENOPAUSE; METABOLIC SYNDROME X; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY;

ADMINISTRATION, CUTANEOUS; ADULT; ARGININE; BIOLOGICAL MARKERS; BODY MASS INDEX; CHOLESTEROL, HDL; DOUBLE-BLIND METHOD; ESTRADIOL; FALLOPIAN TUBES; FEMALE; HOMOCYSTEINE; HUMANS; HYSTERECTOMY; MENOPAUSE, PREMATURE; METABOLIC SYNDROME X; MIDDLE AGED; OVARIECTOMY; PROSPECTIVE STUDIES; TIME FACTORS; TRIGLYCERIDES;

EID: 75149168909     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697130902914650     Document Type: Article

References (44)

1. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992;339:572-575
2. Böger RH, Bode-Boger SM, Szuba A, et al. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 1998;98: 1842-1847
3. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation 1999;99:1141-1146 (Pubitemid 29120084)
4. Cooke JP. Does ADMA cause endothelial dysfunction? Arterioscler Thromb Vasc Biol 2000;20:2032-2037
5. Valkonen VP, Paiva H, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 2001; 358:2127-2128
6. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006;26:2536-2540
7. Bae SW, Stuhlinger MC, Yoo HS, et al. Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatment. Am J Cardiol 2005; 95:729-733
8. Lundman P, Eriksson MJ, Stuhlinger M, Cooke JP, Hamsten A, Tornvall P. Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol 2001;38:111-116
9. Stuhlinger MC, Oka RK, Graf EE, et al. Endothelial dysfunction induced by hyperhomocyst( e)inemia: role of asymmetric dimethylarginine. Circulation 2003;108:933-938
10. Krzyzanowska K, Mittermayer F, Wolzt M, Schernthane G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007;30:1834-1839 (Pubitemid 47036360)
11. el-Swefy SE, Ali SI, Asker ME, Mohamed HE. Hyperhomocysteinaemia and cardiovascular risk in female ovariectomized rats: role of folic acid and hormone replacement therapy. J Pharm Pharmacol 2002;54:391-397
12. de Kraker AT, Kenemans P, Smolders RG, Kroeks MV, van der Mooren MJ. Short-term effects of two continuous combined oestrogenprogestogen therapies on several cardiovascular risk markers in healthy postmenopausal women: a randomised controlled trial. Eur J Obstet Gynecol Reprod Biol 2009;142:139-144
13. Lacut K, Oger E, Abalain JH, Moineau MP, Mottier D; SARAH Investigators. Effects of oral and transdermal 17 beta-estradiol combined with progesterone on homocysteine metabolism in postmenopausal women: a randomised placebo-controlled trial. Atherosclerosis 2004; 174:173-180
14. Smolders RG, de Meer K, Kenemans P, Jakobs C, Kulik W, van der Mooren MJ. Oral estradiol decreases plasma homocysteine, vitamin B6, and albumin in postmenopausal women but does not change the whole-body homocysteine remethylation and transmethylation flux. J Clin Endocrinol Metab 2005;90:2218-2224
15. Smolders RG, van der Mooren MJ, Sipkema P, Kenemans P. Estrogens, homocysteine, vasodilatation and menopause: basic mechanisms, interactions and clinical implications. Gynecol Endocrinol 2003;17:339-354
16. Herrington DM, Braden GA, Williams JK, Morgan TM. Endothelial-dependent coronary vasomotor responsiveness in postmenopausal women with and without estrogen replacement therapy. Am J Cardiol 1994;73:951-952
17. Hulley S, Grady D, Bush T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA 1998;280:605-613
18. Clarke SC, Kelleher J, Lloyd-Jones H, Slack M, Schofiel PM. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study. Br J ObstetGynaecol 2002;109:1056-1062
19. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications: Report of a WHO Consultation. Part 1: Diagnosis and classification of diabetes mellitus. Geneva, Switzerland: World Health Organization, 1999
20. Matthews DR, Hosker JP, Rudenski A, Turner RC. Homeostasis model assessment: insulin resistance and beta cell function in man. Diabeteologia 1985;28:401-411
21. Valtonen P, Karppi J, Nyyssönen K, Valkonen VP, Halonen T, Punnonen K. Comparison of HPLC method and commercial ELISA assay for asymmetric dimethylarginine (ADMA) determination in human serum. J Chromatogr B 2005; 828:97-102
22. Falcone T,Walters MD. Hysterectomy for benign disease. Obstet Gynecol 2008;111:753-767
23. Zhang Y, Lee ET, Cowan LD, North KE, Wild RA, Howard BV. Hysterectomy prevalence and cardiovascular disease risk factors in American Indian women. Maturitas 2005;52:328-336
24. Orozco LJ, Salazar A, Clarke J, Tristan M. Hysterectomy versus hysterectomy plus oophorectomy for premenopausal women. Cochrane Database Syst Rev 2008;16:CD005638
25. Antonicelli R, Olivieri F, Morichi V, Urbani E, Mais V. Prevention of cardiovascular events in early menopause: a possible role for hormone replacement therapy. Int J Cardiol 2008;130: 140-146
26. Sydow K, Schwedhelm E, Arakawa N, et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia. Effects of L-arginine and B vitamins. Cardiovasc Res 2003;57:244-252
27. Abbasi F, Asagmi T, Cooke JP, et al. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001;88:1201-1203
28. Veresh Z, Racz A, Lotz G, Koller A. ADMA impairs nitric oxide-mediated arteriolar function due to increased superoxide production by angiotensin II-NAD(P)H oxidase pathway. Hypertension 2008;52:960-966
29. Furuki K, Adachi H, Enomoto M, et al. Plasma level of asymmetric dimethylarginine (ADMA) as a predictor of carotid intima-media thickness progression: six-year prospective study using carotid ultrasonography. Hypertens Res 2008; 31:1185-1189
30. Lu TM, Ding YA, Charng MJ, Lin SJ. Asymmetrical dimethylarginine: a novel risk factor for coronary artery disease. Clin Cardiol 2003;26: 458-464
31. Teerlink T, Neele SJ, de Jong S, Netelenbos JC, Stehouwer CD. Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) 2003;105:67-71
32. VerhoevenMO,HemelaarM, van derMoorenMJ, Kenemans P, Teerlink T. Oral, more than transdermal, oestrogen therapy lowers asymmetric dimethylarginine in healthy postmenopausal women: a randomized, placebo-controlled study. J Intern Med 2006;259:199-208
33. Achan V, Broadhead M, Malaki M, et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-1459
34. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol 2001;8:679-683
35. Stühlinger MC, Tsao PS, Her JH, Kimoto M, Balint RF, Cooke JP. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation 2001;104: 2569-2575
36. EviöS, Tiitinen A, Turpeinen U, Ylikorkala O. Failure of the combination of sequential oral and transdermal estradiol plus norethisterone acetate to affect plasma homocysteine levels. Fertil Steril 2000;74:1080-1083
37. Vigna GB, Donegà P, Zanca R, et al. Simvastatin, transdermal patch, and oral estrogenprogestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial. Metabolism 2002;51:1463-1470
38. Mijatovic V, Kenemans P, Netelenbos C, et al. Postmenopausal oral 17beta-estradiol continuously combined with dydrogesterone reduces fasting serum homocysteine levels. Fertil Steril 1998;69:876-882
39. Chiantera V, Sarti CD, Fornaro F, et al. Longterm effects of oral and transdermal hormone replacement therapy on plasma homocysteine levels. Menopause 2003;10:286-291
40. Zegura B, Guzic-Salobir B, Sebestjen M, Keber I. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. Menopause 2006;13:643-650
41. Vrablik M, Fait T, Kovar J, Poledne R, Ceska R. Oral but not transdermal estrogen replacement therapy changes the composition of plasma lipoproteins. Metabolism 2008;57:1088-1092
42. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Postgrad Med J 2008; 84:590-598
43. Hausenloy DJ, Yellon DM. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels. Heart 2008;94: 706-714
44. Nanda S, Gupta N, Mehta HC, Sangwan K. Effect of oestrogen replacement therapy on serum lipid profile. Aust NZ J Obstet Gynaecol 2003;43:213-216